General Electric Company (NYSE:GE) announced the appointment of Charles Koontz as president and CEO of GE Healthcare IT and GE Healthcare Chief Digital Officer, effective March 14. Koontz succeeds Jan De Witte, who is leaving GE.

Koontz joins GE from Computer Sciences Corp (CSC) and CSRA, where he was Executive Vice President of the Federal Civilian Agencies Group. As VP and General Manager of the Healthcare group at CSC, Charles focused on transitioning healthcare clients to next generation IT, mobile and cloud technology, and applying real-time analytics to measure clinical and performance outcomes.

Prior to this, Charles led the health practice at Booz Hamilton, where he built a health analytics business working with Fortune 500 healthcare companies and government organizations. His 30-year tenure in technology innovation also includes leadership roles with SAIC, Capgemini and Ernst & Young. He holds a bachelor of science degree in engineering from The Ohio State University. (Original Source)

Shares of General Electric are currently trading at $0.11, up $0.05 or 0.17%. GE has a 1-year high of $31.49 and a 1-year low of $19.37. The stock’s 50-day moving average is $28.73 and its 200-day moving average is $28.08.

On the ratings front, General Electric has been the subject of a number of recent research reports. In a report issued on January 26, Oppenheimer analyst Christopher Glynn reiterated a Hold rating on GE. Separately, on January 25, RBC’s Deane Dray reiterated a Buy rating on the stock and has a price target of $33.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Christopher Glynn and Deane Dray have a total average return of 14.6% and 2.2% respectively. Glynn has a success rate of 72.7% and is ranked #1 out of 3712 analysts, while Dray has a success rate of 59.4% and is ranked #1364.

Overall, 3 research analysts have assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $32.00 which is 6.1% above where the stock opened today.